间充质干细胞源性外泌体治疗角膜及眼表疾病的研究进展

Research progress on mesenchymal stem cells derived exosomes in the treatment of corneal and ocular surface diseases

间充质干细胞(MSCs)来源的外泌体可通过携带的蛋白或核酸等物质调节局部炎症反应、血管生成及免疫应答,从而为角膜外伤、干眼及免疫性眼病等的治疗提供了新思路。外泌体非细胞的特性避免了干细胞治疗中细胞存活、肿瘤发生及移植物排斥等问题,并且有成为治疗药物的生物载体的潜力。本文拟介绍近年来间充质干细胞源外泌体在角膜及眼表疾病治疗方面的研究进展。

Mesenchymal stem cells derived exosomes can regulate inflammatory response,angiogenesis and immune response by carrying proteins and nucleic acids.It provides a brand new idea for the treatment of corneal injury,dry eye and immune-mediated eye diseases.Besides the cell-free nature of exosomes in circumventing the problems of cell survival,tumorigenesis and graft rejection,it has the potential to become a biological carrier of therapeutic drugs.This article introduces the recent progress of mesenchymal stem cells derived exosomes in the treatment of corneal and ocular surface diseases.